BioVie Interview to Air on Bloomberg International on the RedChip Money Report
October 30 2020 - 8:00AM
BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a
clinical-stage company developing innovative drug therapies for
liver disease, today announced an interview with Terren Peizer,
Chairman and Chief Executive Officer, will air on The RedChip
Money Report television program this Sunday November 1st. The
RedChip Money Report airs in 100 million homes on Sundays at 6 p.m.
local time in every country in Europe on Bloomberg International.
In the exclusive interview, Peizer discusses the
Company’s development of BIV201, an orphan drug candidate for the
treatment of ascites due to advanced liver cirrhosis, and upcoming
milestones.
To view the interview segment, please visit:
https://youtu.be/xxzTsexijPU.
“The RedChip Money Report" delivers insightful
commentary on small cap investing, interviews with Wall Street
analysts, financial book reviews, as well as featured interviews
with executives of public companies.
About BioVie and BIV201
BioVie Inc. is developing BIV201 (continuous infusion
terlipressin) an Orphan Drug candidate for the treatment of ascites
due to advanced liver cirrhosis. First-to-market Orphan therapies
typically receive 7 years of market exclusivity in the US for the
designated use. The initial disease target for BIV201 therapy is
ascites, which is a serious complication of advanced liver
cirrhosis, and future development opportunities include hepatorenal
syndrome (HRS) and other life-threatening complications. The
Company plans to commence its second US Phase 2 clinical trial by
the end of this year. The trial design is summarized
on www.clinicaltrials.gov, trial identifier NCT04112199. The
FDA has never approved any drug specifically for treating ascites,
and the Company is not aware of any competing drugs in late-stage
development for ascites. The active agent in BIV201, terlipressin,
is approved for use in about 40 countries for the treatment of
related complications of advanced liver cirrhosis but is not
available in the US or Japan.
The Company has invented a patent-pending
prefilled syringe that has been cleared for use in our upcoming
Phase 2 trial subject to certain additional standard analytical
tests. This novel BIV201 delivery system is expected to greatly
simplify at-home patient treatment and improve patient compliance
by enabling easy injection of the liquid concentrate into the IV
bag connected to the infusion pump. Room temperature stability has
been achieved for 9 months providing an important advantage
because, to the best of the Company's knowledge, all other
terlipressin products sold globally must be stored under
refrigeration. The novel prefilled syringe format also avoids the
manual mixing of minute (2 – 4 mg) quantities of terlipressin
powder in saline solution, thereby reducing the possibility of
dosing errors during reconstitution and improving sterility. BioVie
has begun applying for global patent protection for this novel
terlipressin delivery system. The Company has also received Orphan
Drug designation for the treatment of hepatorenal syndrome (HRS)
and has FDA Fast Track status. For more information,
visit http://www.biovieinc.com/.
Forward-Looking Statements
This press release contains forward-looking
statements, which may be identified by words such as "expect,"
"look forward to," "anticipate" "intend," "plan," "believe,"
"seek," "estimate," "will," "project" or words of similar meaning.
Although BioVie Inc. believes such forward-looking statements are
based on reasonable assumptions, it can give no assurance that its
expectations will be attained. Actual results may vary materially
from those expressed or implied by the statements herein due to the
Company's ability to successfully raise sufficient capital on
reasonable terms or at all, available cash on hand and contractual
and statutory limitations that could impair our ability to pay
future dividends, our ability to complete our clinical trials
and to obtain approval for our product candidates, to successfully
defend potential future litigation, changes in local or national
economic conditions as well as various additional risks, many
of which are now unknown and generally out of the Company's
control, and which are detailed from time to time in reports filed
by the Company with the SEC, including quarterly reports on Form
10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie
Inc. does not undertake any duty to update any statements contained
herein (including any forward-looking statements), except as
required by law.
Contact:
INVESTOR RELATIONS:Dave Gentry, CEORedChip Companies
Inc.407-491-4498dave@redchip.com
BioVie (NASDAQ:BIVI)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioVie (NASDAQ:BIVI)
Historical Stock Chart
From Sep 2023 to Sep 2024